<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.109319</article-id><article-id pub-id-type="publisher-id">ACM-37796</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20200900000_28358438.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  Supreme喉罩复合右美托咪定用于脑动脉瘤弹簧圈栓塞术的麻醉
  The Anesthetic Use of Supreme Laryngeal Mask Airway with Dexmedetomidine in the Coiled Embolization of Intracranial Aneurysms
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>储</surname><given-names>琳</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杜</surname><given-names>伟忠</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>苏</surname><given-names>纲</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>兵</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>苏</surname><given-names>平</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>昆明医科大学附属甘美医院麻醉科，昆明市第一人民医院，云南省器官移植临床医学中心，云南 昆明</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>08</day><month>09</month><year>2020</year></pub-date><volume>10</volume><issue>09</issue><fpage>2121</fpage><lpage>2126</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：研究supreme喉罩复合右美托咪定用于脑动脉瘤弹簧圈栓塞术麻醉的临床价值。方法：择期行脑动脉瘤弹簧圈栓塞术患者200例随机分为两组：喉罩复合右美托咪定全麻组(S组)和常规气管插管全麻(D组)。比较两组患者建立气道的时间；比较T
   <sub>0</sub> (基础生命值)；T
   <sub>1</sub> (建立气道前)，T
   <sub>2</sub> (建立气道后)，T
   <sub>3</sub> (动脉瘤栓塞即刻)，T
   <sub>4</sub> (拔出气管导管即刻)：收缩压(SBP)、舒张压(DBP)、心率(HR)的变化；比较术中麻醉药物的用量；比较苏醒期自主呼吸回复和拔管的时间和相关并发症诸如呛咳，咽痛发生的情况。结果：1) S组在建立气道的时间上快于D组(P &lt; 0.05)；2) 围术期中S组的血压更平稳，组内比较无显著性差异(P &gt; 0.05)，而D组血压波动大，尤其是在建立气道和拔出导管后，与诱导前有显著性差异(P &lt; 0.01)；3) 两组在麻醉用药的总量肌肉松弛药及其拮抗药的用量上S组与D组间有显著性差异(P &lt; 0.05)；4) 术后苏醒时间，呛咳，躁动和术后并发症的发生率上S组明显少于D组，且有显著性差异(P &lt; 0.05)。结论：supreme喉罩复合右美托咪定用于脑动脉瘤弹簧圈栓塞术的麻醉方法，不但简便易行，刺激小，循环平稳，术后并发症发生少，有临床推广的价值。
    Objective: To discuss the clinical application of supreme laryngeal mask airway with dexmedetomidine anesthesia in the embolization of intracranial aneurysms. Methods: Two hundred patients scheduled for interventional divided into 2 groups (n = 100 each): LMA with dexmedetomidine (S group) and endotracheal intubation group (D group). Comparing the time of establishing the airway, the systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR) during perioperation, there are basic value (T
   <sub>0</sub>), the before patients induced (T
   <sub>1</sub>), immediation after intubation (T
   <sub>2</sub>), immediation of embolic aneurysm (T
   <sub>3</sub>), tube drawing immediate (T
   <sub>4</sub>); comparing the total anesthetic dosages used, the time for return of spontaneous breathing, the extubation time and the occurrence of adverse effects such as coughing and pharyngodynia. Results: 1) The time of establishing the airway, S group is less than D group (P &lt; 0.05). 2) S group has more stable perioperative hemodynamics. There is no significant difference compared in S group (P &gt; 0.05). But perioperative hemodynamics varies a lot in D group. Especially at intubation and extubation, compared the T0, there is statistically significant difference (P &lt; 0.01); 3) the consumption of anesthetic dosages, the dosages of vacuronium and neostigmine, there is significant difference between S group and D group (P &lt; 0.05). 4) Emergence from anesthesia was faster and occurrence of pharyngodynia was fewer in group S than that in group D. There is significant difference (P &lt; 0.05). Conclusion: The clinical anesthesia use of supreme LMA with dexmedetomidine in the embolization of intracranial aneurysms, in terms of easy placement, less irritation, better hemodynamic profile, faster emergence and less adverse effects, should be promoted. 
  
 
</p></abstract><kwd-group><kwd>Supreme喉罩，右美托咪定，脑动脉瘤，弹簧圈栓塞, Supreme LMA</kwd><kwd> Dexmedetomidine</kwd><kwd> Intracranial Anearysms</kwd><kwd> Coiled Embolization</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：研究supreme喉罩复合右美托咪定用于脑动脉瘤弹簧圈栓塞术麻醉的临床价值。方法：择期行脑动脉瘤弹簧圈栓塞术患者200例随机分为两组：喉罩复合右美托咪定全麻组(S组)和常规气管插管全麻(D组)。比较两组患者建立气道的时间；比较T<sub>0</sub> (基础生命值)；T<sub>1</sub> (建立气道前)，T<sub>2</sub> (建立气道后)，T<sub>3</sub> (动脉瘤栓塞即刻)，T<sub>4</sub> (拔出气管导管即刻)：收缩压(SBP)、舒张压(DBP)、心率(HR)的变化；比较术中麻醉药物的用量；比较苏醒期自主呼吸回复和拔管的时间和相关并发症诸如呛咳，咽痛发生的情况。结果：1) S组在建立气道的时间上快于D组(P &lt; 0.05)；2) 围术期中S组的血压更平稳，组内比较无显著性差异(P &gt; 0.05)，而D组血压波动大，尤其是在建立气道和拔出导管后，与诱导前有显著性差异(P &lt; 0.01)；3) 两组在麻醉用药的总量肌肉松弛药及其拮抗药的用量上S组与D组间有显著性差异(P &lt; 0.05)；4) 术后苏醒时间，呛咳，躁动和术后并发症的发生率上S组明显少于D组，且有显著性差异(P &lt; 0.05)。结论：supreme喉罩复合右美托咪定用于脑动脉瘤弹簧圈栓塞术的麻醉方法，不但简便易行，刺激小，循环平稳，术后并发症发生少，有临床推广的价值。</p></sec><sec id="s2"><title>关键词</title><p>Supreme喉罩，右美托咪定，脑动脉瘤，弹簧圈栓塞</p></sec><sec id="s3"><title>The Anesthetic Use of Supreme Laryngeal Mask Airway with Dexmedetomidine in the Coiled Embolization of Intracranial Aneurysms</title><p>Lin Chu<sup>*</sup>, Weizhong Du, Gang Su, Bin Li, Ping Su</p><p>Department of Anesthesiology, Affiliated Calmette Hospital of Kunming Medical University, Kunming First People’s Hospital, The Organ Transplant Clinical Medical Center of Yunnan Province, Kunming Yunnan</p><p><img src="//html.hanspub.org/file/39-1571543x5_hanspub.png" /></p><p>Received: Sep. 2<sup>nd</sup>, 2020; accepted: Sep. 17<sup>th</sup>, 2020; published: Sep. 24<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/39-1571543x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To discuss the clinical application of supreme laryngeal mask airway with dexmedetomidine anesthesia in the embolization of intracranial aneurysms. Methods: Two hundred patients scheduled for interventional divided into 2 groups (n = 100 each): LMA with dexmedetomidine (S group) and endotracheal intubation group (D group). Comparing the time of establishing the airway, the systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR) during perioperation, there are basic value (T<sub>0</sub>), the before patients induced (T<sub>1</sub>), immediation after intubation (T<sub>2</sub>), immediation of embolic aneurysm (T<sub>3</sub>), tube drawing immediate (T<sub>4</sub>); comparing the total anesthetic dosages used, the time for return of spontaneous breathing, the extubation time and the occurrence of adverse effects such as coughing and pharyngodynia. Results: 1) The time of establishing the airway, S group is less than D group (P &lt; 0.05). 2) S group has more stable perioperative hemodynamics. There is no significant difference compared in S group (P &gt; 0.05). But perioperative hemodynamics varies a lot in D group. Especially at intubation and extubation, compared the T<sub>0</sub>, there is statistically significant difference (P &lt; 0.01); 3) the consumption of anesthetic dosages, the dosages of vacuronium and neostigmine, there is significant difference between S group and D group (P &lt; 0.05). 4) Emergence from anesthesia was faster and occurrence of pharyngodynia was fewer in group S than that in group D. There is significant difference (P &lt; 0.05). Conclusion: The clinical anesthesia use of supreme LMA with dexmedetomidine in the embolization of intracranial aneurysms, in terms of easy placement, less irritation, better hemodynamic profile, faster emergence and less adverse effects, should be promoted.</p><p>Keywords:Supreme LMA, Dexmedetomidine, Intracranial Anearysms, Coiled Embolization</p><disp-formula id="hanspub.37796-formula34"><graphic xlink:href="//html.hanspub.org/file/39-1571543x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/39-1571543x8_hanspub.png" /> <img src="//html.hanspub.org/file/39-1571543x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>近年来，随着DSA (数字减影血管造影)和神经介入技术的飞速发展，颅内动脉瘤的诊断与治疗也较前明显增加，该类手术多在介入室中完成，通常介入室远离手术室，因此对于麻醉技术及安全性提出了很大的挑战，此类手术要求麻醉深浅适宜，尤其是诱导期要求循环平稳，以减少动脉瘤破裂，术中要求病人严格制动，以保证微导管、弹簧圈、和支架的准确到位和放置，术后快速苏醒以便评估手术效果。右美托咪定作为一种新型α<sub>2</sub>肾上腺素受体激动剂，右美托咪定具有良好的镇静及镇痛作用，对儿茶酚胺的释放产生良好的调控作用，有助于控制患者血压水平。国内外大量研究表明，右美托咪定具有抗交感、抗炎、抗氧化等作用，因而对心脏、脑、肝脏、肾脏、肺脏、肠等多个器官具有一定的保护作用。有报道指出 [<xref ref-type="bibr" rid="hanspub.37796-ref1">1</xref>]，该药物对脑海马具有保护功能，并且在动物实验中也发现该药物有预防局部脑神经损伤的功能。因此本研究意在观察并讨论supreme喉罩复合右美托咪定用于脑动脉瘤弹簧圈栓塞术时的临床效果观察。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 研究对象</title><p>选择2018年5月~2020年4月我院择期颅内动脉瘤弹簧圈栓塞患者共计200例，年龄18~65岁，ASA Ⅰ-Ⅲ级，男87例，女113例；随机分成两组：supreme喉罩复合右美托咪定组(S组喉罩组实验组)和常规麻醉组(D组气管插管组对照组)，每组各100例。实验组：女63例，男37例；平均年龄(56 &#177; 6)岁，对照组：女29例，男71例；平均年龄(58 &#177; 5)岁。两组患者的性别、年龄、BMI值、ASA分级等临床资料比较无明显差异，无临床和统计学的意义(p &gt; 0.05)。</p><p>排除标准：窦性心动过缓，束支传导阻滞，严重肝肾功能障碍，急诊未禁食的高危患者；手术时长超过2.5小时，过度肥胖，有增加反流误吸及通气困难等均排除。</p><p>本研究经昆明医科大学附属甘美医院伦理委员会批准，并与患者签署知情同意书。</p></sec><sec id="s6_2"><title>2.2. 麻醉方法</title><p>术前患者常规禁食禁饮，入室后开放静脉置18#静脉留置针，以5 ml/kg∙h静脉输注复方氯化钠液，监测心电图(ETG)，血压(BP)，心率(HR)，呼吸(R)，血氧饱和度(SPO<sub>2</sub>)，体温(T)，稳定后记录基础生命指标。用舒芬太尼，维库溴铵，丙泊酚诱导5 min后建立气道。S组插入supreme喉罩，D组经口明视气管插管后接Drager麻醉机控制呼吸，并监测控制P<sub>ET</sub>CO<sub>2</sub>在正常范围。S组给予右美托咪定负荷剂量1 &#181;g/kg输注，10分钟后以0.3 &#181;g/kg∙h<sup>−1</sup>持续泵入，两组均以丙泊酚4~6 &#181;g/kg∙h<sup>−1</sup>及瑞芬太尼3 &#181;g/kg∙h<sup>−1</sup>静脉泵入，必要时静脉间断注入舒芬太尼维持术中麻醉。必要时给予血管活性药物以避免血压波动过大。</p></sec><sec id="s6_3"><title>2.3. 评价方法</title><p>记录BP，HR，ECG，SPO<sub>2</sub>，基础生命值(T<sub>0</sub>)；T<sub>1</sub> (建立气道前)，T<sub>2</sub> (建立气道后)，T<sub>3</sub> (动脉瘤栓塞即刻)，T<sub>4</sub> (拔出气管导管后1 min)，5个时间点的BP，HR；记录术中维库溴铵的用量；观察两组在建立气道的时间，诱导和弹簧圈置入及术毕拔管时的循环波动及拔管时间，清醒时间，呛咳，咽痛，恶心，呕吐，躁动等并发症的发生。</p></sec><sec id="s6_4"><title>2.4. 统计学处理</title><p>采用SPSS 18.0统计学软件对数据进行分析，计量资料以均数 &#177; 标准差( x &#177; s )表示，组内均数的比较采用配对资料t检验，组间比较采用样本均数t检验；计数资料用百分率表示，组间率的比较采用χ<sup>2</sup>检验，以P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><p>一般情况比较，两组患者性别，年龄，体重指数，ASA分级，麻醉时间，手术时间，和高血压情况的比较，差异无统计学意义(P &gt; 0.05)具有可比性见表1。S组在建立气道的时间上快于D组(P &lt; 0.05)见表2；围术期中S组的血压更平稳，组内比较无显著性差异(P &gt; 0.05)，而D组血压波动大，尤其是在建立气道和拔出导管后，与诱导前有显著性差异(P &lt; 0.01)见表3；两组在麻醉用药的总量肌肉松弛药及其拮抗药的用量上S组与D组间有显著性差异(P &lt; 0.05)见表4；术后苏醒时间，呛咳，躁动和术后并发症的发生率上S组明显少于D组，且有显著性差异(P &lt; 0.05)见表5、表6。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of general conditions between the two group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >男/女(例)</th><th align="center" valign="middle" >年龄(岁)</th><th align="center" valign="middle" >BMI</th><th align="center" valign="middle" >ASA Ⅰ/Ⅱ (例)</th><th align="center" valign="middle" >麻醉时间(h)</th><th align="center" valign="middle" >手术时间(h)</th><th align="center" valign="middle" >高血压(例)</th></tr></thead><tr><td align="center" valign="middle" >S组</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >37/63</td><td align="center" valign="middle" >56 &#177; 6</td><td align="center" valign="middle" >21.3 &#177; 1.6</td><td align="center" valign="middle" >59/41</td><td align="center" valign="middle" >2.6 &#177; 0.4</td><td align="center" valign="middle" >2.2 &#177; 0.4</td><td align="center" valign="middle" >78</td></tr><tr><td align="center" valign="middle" >D组</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >29/71</td><td align="center" valign="middle" >58 &#177; 5</td><td align="center" valign="middle" >21.2 &#177; 1.4</td><td align="center" valign="middle" >55/45</td><td align="center" valign="middle" >2.8 &#177; 0.5</td><td align="center" valign="middle" >2.3 &#177; 0.3</td><td align="center" valign="middle" >74</td></tr></tbody></table></table-wrap><p>表1. 两组患者一般情况比较</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of airway establishment time between the two group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >气道建立的时间(s)</th></tr></thead><tr><td align="center" valign="middle" >S组</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >25 &#177; 8.5</td></tr><tr><td align="center" valign="middle" >D组</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >70 &#177; 12.5</td></tr></tbody></table></table-wrap><p>表2. 两组患者建立气道的时间比较</p><p>注：P &lt; 0.05。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Intraoperative hemodynamic changes of patients under general anesthesia in the two groups (X &#177; S</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >指标</th><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >T<sub>0</sub></th><th align="center" valign="middle" >T<sub>1</sub></th><th align="center" valign="middle" >T<sub>2</sub></th><th align="center" valign="middle" >T<sub>3</sub></th><th align="center" valign="middle" >T<sub>4</sub></th></tr></thead><tr><td align="center" valign="middle"  rowspan="2"  >SBP</td><td align="center" valign="middle" >S组</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >145.44 &#177; 11.67</td><td align="center" valign="middle" >136.42 &#177; 12.31</td><td align="center" valign="middle" >133.57 &#177; 7.53</td><td align="center" valign="middle" >118.56 &#177; 8.45</td><td align="center" valign="middle" >128.37 &#177; 9.67</td></tr><tr><td align="center" valign="middle" >D组</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >148.57 &#177; 9.76</td><td align="center" valign="middle" >148.55 &#177; 11.92</td><td align="center" valign="middle" >157.34 &#177; 11.84</td><td align="center" valign="middle" >108.56 &#177; 7.37</td><td align="center" valign="middle" >158.59 &#177; 11.87</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >DBP</td><td align="center" valign="middle" >S组</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >87.76 &#177; 6.78</td><td align="center" valign="middle" >83.64 &#177; 7.55</td><td align="center" valign="middle" >80.22 &#177; 6.67</td><td align="center" valign="middle" >79.36 &#177; 6.41</td><td align="center" valign="middle" >85.78 &#177; 7.66</td></tr><tr><td align="center" valign="middle" >D组</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >88.74 &#177; 10.23</td><td align="center" valign="middle" >84.03 &#177; 6.87</td><td align="center" valign="middle" >102.69 &#177; 10.55</td><td align="center" valign="middle" >72.47 &#177; 5.77</td><td align="center" valign="middle" >90.66 &#177; 10.54</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >HR</td><td align="center" valign="middle" >S组</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >65.29 &#177; 8.67</td><td align="center" valign="middle" >57.35 &#177; 11.06</td><td align="center" valign="middle" >64.29 &#177; 6.83</td><td align="center" valign="middle" >68.36 &#177; 7.56</td><td align="center" valign="middle" >70.68 &#177; 9.78</td></tr><tr><td align="center" valign="middle" >D组</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >70.76 &#177; 6.78</td><td align="center" valign="middle" >73.39 &#177; 7.89</td><td align="center" valign="middle" >89.64 &#177; 8.89</td><td align="center" valign="middle" >74.38 &#177; 8.89</td><td align="center" valign="middle" >87.88 &#177; 7.96</td></tr></tbody></table></table-wrap><p>表3. 两组全麻患者术中血流动力学变化情况(X &#177; S)</p><p>注：与对照组相比，P &lt; 0.05。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Comparison of propofol, remifentanil and vecuronium dosage in the two groups n</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >丙泊酚用量mg</th><th align="center" valign="middle" >瑞芬太尼用量&#181;g</th><th align="center" valign="middle" >维库溴铵用量mg</th></tr></thead><tr><td align="center" valign="middle" >S组</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >398 &#177; 78</td><td align="center" valign="middle" >723 &#177; 74</td><td align="center" valign="middle" >4 &#177; 1</td></tr><tr><td align="center" valign="middle" >D组</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >623 &#177; 112</td><td align="center" valign="middle" >930 &#177; 83</td><td align="center" valign="middle" >7 &#177; 2</td></tr></tbody></table></table-wrap><p>表4. 两组患者丙泊酚，瑞芬太尼和维库溴铵用量比较</p><p>注：与对照组相比，P &lt; 0.05。</p><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Patients in the two groups during the waking period (X &#177; S</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >呼之睁眼时间(min)</th><th align="center" valign="middle" >拔管(喉罩)时间(min)</th><th align="center" valign="middle" >定向力恢复时间(min)</th></tr></thead><tr><td align="center" valign="middle" >S组</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >5.5 &#177; 1.4</td><td align="center" valign="middle" >5.9 &#177; 1.2</td><td align="center" valign="middle" >12.4 &#177; 2.0</td></tr><tr><td align="center" valign="middle" >D组</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >15.8 &#177; 1.9</td><td align="center" valign="middle" >18.2 &#177; 2.7</td><td align="center" valign="middle" >25.8 &#177; 2.9</td></tr></tbody></table></table-wrap><p>表5. 两组患者苏醒期情况(X &#177; S)</p><p>注：P &lt; 0.05。</p><table-wrap id="table6" ><label><xref ref-type="table" rid="table6">Table 6</xref></label><caption><title> Complications in the wake period of patients in the two groups (N</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >呛咳</th><th align="center" valign="middle" >呕吐</th><th align="center" valign="middle" >返流</th><th align="center" valign="middle" >躁动</th><th align="center" valign="middle" >术后咽痛</th></tr></thead><tr><td align="center" valign="middle" >S组</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >5</td></tr><tr><td align="center" valign="middle" >D组</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >98</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >39</td><td align="center" valign="middle" >87</td></tr></tbody></table></table-wrap><p>表6. 两组患者苏醒期并发症发生情况(n)</p><p>注：P &lt; 0.05。</p></sec><sec id="s8"><title>4. 讨论</title><p>颅内动脉瘤多发生在颅内动脉管壁上的异常膨出，是造成蛛网膜下腔出血的首位病因，在脑血管意外中，仅次于脑血栓和高血压脑出血，一旦破裂，死亡率极高。近年来，栓塞技术在治疗颅内动脉瘤方面已经取得较快的发展，我院近2年来共完成颅内动脉瘤栓塞术200余例，治愈率高达90%，手术时间也在不断缩短，因其手术微创，恢复快，因此其麻醉要求与常规开颅手术有明显的区别，要求麻醉深浅适宜，若过深，低血压会影响脑灌注，术前及插管时过浅又会增加动脉瘤破裂再次颅内出血以至患者失去介入治疗的时机，故在插管和拔管期间要保持血流动力学稳定是极为重要的，且在手术中一定要保持足够的麻醉深度，严格避免任何体动的发生和过强的自主呼吸对其手术操作的影响。</p><p>对于气道的建立，气管插管是最为经典的方法，但插管时若麻醉深度掌握不当，最易引起循环剧烈波动，可能造成动脉瘤突然破裂；我院就有一例患者发生上述情况，只有紧急放弃介入栓塞，改开颅血肿清除加动脉瘤夹闭术。而与气管插管相比，插入喉罩时循环波动小，随着喉罩的不断改进与更新，很多学者运用喉罩于脑动脉瘤栓塞手术麻醉，也取得良好的效果 [<xref ref-type="bibr" rid="hanspub.37796-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.37796-ref3">3</xref>]。supreme喉罩是目前最新的一款，该喉罩宽大的椭圆形通气罩以及圆锥形的远端设计，使其囊内压力低，并与喉部周围组织紧密接触，在正压通气或改变体位情况下仍可以保持良好的双重密封性：其一是气道密封，其二是食道密封，前者可以达到最佳通气效果，漏气压可达37 cm H<sub>2</sub>O，后者则可防止反流误吸，且操作简便，无需使用引导工具或喉镜即可完成，一次到位率高，对位准确 [<xref ref-type="bibr" rid="hanspub.37796-ref4">4</xref>]。多项研究表明 [<xref ref-type="bibr" rid="hanspub.37796-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.37796-ref6">6</xref>]，右美托咪定(DEX)通过激动交感神经末梢的突触前膜α<sub>2</sub>肾上腺素能受体，交感神经活性被抑制，去甲肾上腺素的释放减少，血浆中儿茶酚胺溶度降低，在应激状态下不会出现血压和心率异常增高，因此围术期血流动力学相对稳定。右美托咪定的脑保护作用主要通过减少大脑缺血缺氧性损伤，减少缺血再灌注损伤，减少术后认知功能障碍来体现 [<xref ref-type="bibr" rid="hanspub.37796-ref7">7</xref>]。研究表明DEX在维持CBF及脑代谢率(cerebal metabolic rate, CMR)平衡方面可能发挥着积极作用。Chi等 [<xref ref-type="bibr" rid="hanspub.37796-ref8">8</xref>] 通过动物实验证实，出血时使用右美托咪定可减少局部的CBF和CMR，保持脑氧供需平衡状态，发挥神经保护作用。其脑保护作用的机制主要有：1) 降低兴奋性氨基酸(excitatory amino acids, EAA)毒性。而兴奋性氨基酸主要包括谷氨酸(Glu)、天门冬氨酸(Asp)等，谷氨酸介导的兴奋性细胞毒性被认为是脑缺血性损伤的中心环节，其不仅可诱导细胞凋亡，还可直接导致细胞坏死 [<xref ref-type="bibr" rid="hanspub.37796-ref9">9</xref>]。研究表明，DEX 可通过抑制电压门控性钙通道活性及促分裂原活化蛋白激酶的活性，阻止钙离子过度聚集，抑制谷氨酸的释放而发挥神经保护作用 [<xref ref-type="bibr" rid="hanspub.37796-ref10">10</xref>]。此外，DEX与α<sub>2</sub>-A亚型受体结合可降低脑组织中兴奋性氨基酸的释放，激活谷氨酰胺酶活性，增强星形胶质细胞对谷氨酸氧化代谢的能力，而减轻其兴奋性毒性 [<xref ref-type="bibr" rid="hanspub.37796-ref11">11</xref>]。2) 降低炎症反应，杨桐榉等 [<xref ref-type="bibr" rid="hanspub.37796-ref12">12</xref>] 对脑缺血再灌损伤大鼠行DEX干预后，大脑皮层区神经细胞损伤和凋亡也明显减轻，其机制可能与抑制NF-κB磷酸化，抑制小胶质细胞活化，减少TNF-α的表达，发挥抗炎作用有关。3) 抗氧化应激及抗凋亡，钱宝民等 [<xref ref-type="bibr" rid="hanspub.37796-ref13">13</xref>] 研究也证明DEX可通过减少氧自由基的生成，抑制脂质过氧化反应，上调内源性抗氧化物酶活性减轻海马CA1区的氧化应激损伤，促进神经功能障碍恢复。但目前更深层次的机制研究多局限于动物实验，未来应对其使用剂量、时限及与其他药物的相互作用等进行更细致的多中心大样本研究，以增加其在临床应用的安全性和有效性。另外，由于右美托咪定的抗交感神经兴奋作用而引起反馈性的迷走神经兴奋，致使心率减慢，在本实验研究中，再加上舒芬太尼的使用，患者发生心率减慢的比率增加，因此多数需用阿托品提高心率。</p><p>右美托咪定抑制大脑体温调节中枢，抑制体温信息在脊髓水平的传入，使寒战阈值提高，从而抑制寒战的发生 [<xref ref-type="bibr" rid="hanspub.37796-ref14">14</xref>]，因此，患者可以在舒适安静的情况下拔管，明显提高复苏时拔管的安全性和舒适度。</p><p>因此通过结合supreme喉罩及右美托咪定在颅内动脉瘤弹簧圈栓塞术中的应用观察，我们找到了一种更符合该类手术的麻醉方法，因其方便，易行且安全并发症少，在此与大家交流分享；但其中仍存在一些研究的局限性问题，诸如术中循环不够平稳，需要辅以血管活性药物处理，术后气道分泌物多，术后部分患者有胃胀气的不适症状，以及supreme喉罩的如何恰当的选择，而不单单只根据体重作为参考指标 [<xref ref-type="bibr" rid="hanspub.37796-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.37796-ref16">16</xref>] 等仍有很多值得考虑和改进的地方。</p></sec><sec id="s9"><title>文章引用</title><p>储 琳,杜伟忠,苏 纲,李 兵,苏 平. Supreme喉罩复合右美托咪定用于脑动脉瘤弹簧圈栓塞术的麻醉The Anesthetic Use of Supreme Laryngeal Mask Airway with Dexmedetomidine in the Coiled Embolization of Intracranial Aneurysms[J]. 临床医学进展, 2020, 10(09): 2121-2126. https://doi.org/10.12677/ACM.2020.109319</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.37796-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">宋允. 颅内动脉瘤手术患者应用右美托咪定对患者脑保护的作用分析[J]. 中国医药指南, 2016, 14(8): 119-120.</mixed-citation></ref><ref id="hanspub.37796-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">李晓宁, 蔡明. 喉罩在颅内动脉瘤介入手术麻醉中的效果观察[J]. 河南外科学杂志, 2014, 20(4): 55-56.</mixed-citation></ref><ref id="hanspub.37796-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">王妮荣, 吉宗民. 喉罩全麻在老年脑动脉瘤患者介入栓塞术中的应用效果[J]. 临床军医杂志, 2015, 43(11): 1111-1114.</mixed-citation></ref><ref id="hanspub.37796-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Wong, D.T., Yang, J.J. and Jagannathan, N. (2012) Brief Review: The LMA Supreme™ Supraglottic Airway. Canadian Journal of Anesthesia, 59, 483-493. &lt;br&gt;https://doi.org/10.1007/s12630-012-9673-0</mixed-citation></ref><ref id="hanspub.37796-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Tanskanen, P.E., Kytt, J.V., Randell, T.T. and Aantaa, R.E. (2006) Dexmedetomidine as an Anaesthetic Adjuvant in Patients Undergoing Intraeranial Tumour Surgery: A Double-Blind, Randomized and Placebo-Controlled Study. British Journal of Anaesthesia, 97, 658-665. &lt;br&gt;https://doi.org/10.1093/bja/ael220</mixed-citation></ref><ref id="hanspub.37796-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Ma, D.Q., Hossain, M., Rajakumaraswamy, N., et al. (2004) Dexmedetomidine Produces Its Neuroprotective Effect via the α2A-Adrenoceptor Subtype. European Journal of Pharmacology, 502, 87-97. 
&lt;br&gt;https://doi.org/10.1016/j.ejphar.2004.08.044</mixed-citation></ref><ref id="hanspub.37796-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">陈牡林, 李跃祥. 右美托咪定脑保护作用及机制的研究进展[J]. 中国处方药, 2020, 18(2): 20-22.</mixed-citation></ref><ref id="hanspub.37796-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Chi, O.Z., Hunter, C., Liu, X., et al. (2011) The Effects of Dexmedetomidine on Regional Cerebral Blood Flow and Oxygen Consumption During Severe Hemorrhagic Hypotension in Rats. Anesthesia &amp; Analgesia, 113, 349-355.  
&lt;br&gt;https://doi.org/10.1213/ANE.0b013e31822071db</mixed-citation></ref><ref id="hanspub.37796-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">沈瑞乐, 郭铁, 滕军放. 慢性脑缺血老龄大鼠海马NMDA受体亚单位NR2B表达的特征[J]. 中国实用神经疾病杂志, 2008, 11(3): 24-26.</mixed-citation></ref><ref id="hanspub.37796-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">万孟宁, 田泽丹, 陈玉培. 右美托咪定发挥脑保护作用的研究进展[J]. 重庆医科大学学报, 2016, 41(5): 533-536.</mixed-citation></ref><ref id="hanspub.37796-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Degos, V., Charpentier, T.L., Chhor, V., et al. (2013) Neuroprotective Effects of Dexmedetomidine against Glutamate Agonist-Induced Neuronal Cell Death Are Related to Increased Astrocyte Brain-Derived Neurotrophic Factor Expression. Anesthesiology, 118, 1123-1132. &lt;br&gt;https://doi.org/10.1097/ALN.0b013e318286cf36</mixed-citation></ref><ref id="hanspub.37796-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">杨桐榉, 王凯, 王震, 等. 右美托咪定抑制小胶质细胞活化发挥脑保护作用的实验研究[J]. 第三军医大学学报, 2018, 40(23): 2197-2203.</mixed-citation></ref><ref id="hanspub.37796-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">钱宝民, 高清丽, 房立峰, 等. 右美托咪定对创伤性脑损伤大鼠认知功能和海马CA1区氧化应激的影响[J]. 临床麻醉学杂志, 2015, 31(8): 801-805.</mixed-citation></ref><ref id="hanspub.37796-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Phan, H. and Hnahata, M.C. (2008) Clinical Uses of Dexmedetomidine in Pediatric Patients. Paediatric Drugs, 10, 49-69. &lt;br&gt;https://doi.org/10.2165/00148581-200810010-00006</mixed-citation></ref><ref id="hanspub.37796-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Weng, M.1., Ding, M., Xu, Y., Yang, X.J., Li, L.H., Zhong, J. and Miao, C.H. (2016) An Evaluation of Thyromental Distance-Based Method or Weight-Based Method in Determining the Size of the Laryngeal Mask Airway Supreme: A Randomized Controlled Study. Medicine (Baltimore), 95, e2902.</mixed-citation></ref><ref id="hanspub.37796-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">杜素贞, 田鸣. Supreme喉罩型号与垂中距的关系[J]. 临床麻醉学杂志, 2016, 12(32): 1223-1224.</mixed-citation></ref></ref-list></back></article>